The company plans to file an IND in the second half of 2019. The company CEO says the "CAAR-T" therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.
Experts say proliferation of products makes standardization crucial, as ballooning complexity risks overwhelming apheresis centers and forcing service cuts.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Still, despite costs largely in line with the therapy's benefits, the study's author and another expert said reimbursement models have not kept up and need improvement.